Cabaletta Bio (NASDAQ: CABA) announced today that it priced a $150 million stock offering, selling more than 51 million shares at $2.90 each. 

‍

The capital raise was done at market price and includes participation from existing investors and new institutional funds, including a large pharmaceutical backer.

‍

Here’s how the market reacted …

‍

‍

Cabaletta is a clinical-stage biotech developing engineered T-cell therapies for the treatment of autoimmune diseases.  Its lead program, rese-cel, is being tested in conditions like lupus and myasthenia gravis.

‍

Resetting the immune system

‍

The idea is pretty straightforward.

‍

Instead of managing autoimmune diseases with long-term drugs, Cabaletta aims to reset the immune system with a one-time cell therapy.

‍

That’s the upside.

‍

The risk, however, is that these treatments are still in early clinical testing.

‍

That said, it looks like some pretty deep-pocketed investors see this as a worthwhile risk-versus-reward proposition.  And that’s not a trivial observation.

‍

The $150 million offering will be used to continue clinical trials, expand manufacturing capabilities, and fund operations into roughly mid-2027.

‍

Worth noting: last week, Cabaletta Bio and Cellares signed a 10-year commercial supply agreement to scale Rese-cel.

‍

Under the terms of the deal, Cellares will serve as the long-term manufacturing partner, using automated production platforms to supply the therapy at scale, potentially supporting thousands of treatment batches per year while reducing labor and per-unit costs compared to traditional methods. 

‍

The structure is designed to solve a key bottleneck in cell therapy: scalability.

‍

The timing on this is not coincidental.

‍